Ascendis Pharma A/S reports results for the quarter ended in March - Earnings Summary

Ascendis Pharma A/S

02/05/2024 23:35

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €2.30​​ per share for the quarter ended in March, lower than
the same quarter last year, when the company reported EPS of
$-1.98.  The mean expectation of eleven analysts for the quarter
was for a loss of €1.50 per share. Wall Street expected
results to range from €-1.85 to -93 cents per share.
    * Revenue rose 185.5% to €95.89 million from a year ago;
analysts
expected €79.49 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
$2.30​.
    * The company reported a quarterly loss of €131.04 million.
    * Ascendis Pharma A/S shares had fallen by 6.7% this
quarter and
gained 12.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 13.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Ascendis Pharma
A/S is $171.76 
This summary was machine generated from LSEG data May 2 at 10:35
p.m. UTC. ​All figures in euros unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -1.50          -2.30          Missed
 Dec. 31 2023      -2.03          -1.54          Beat
 Sep. 30 2023      -2.38          -2.88          Missed
 Jun. 30 2023      -2.59          -2.16          Beat